ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,441.17
0.25%
Dow Jones
40,003.59
0.00%
Gold vs US Dollar
2,428.82
0.38%
Brent Oil
83.605
0.01%
Bitcoin
67,003.80
1.28%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Biogen Inc (BIIB)

  7. Biogen Inc (BIIB) News

Biogen (BIIB)

Biogen Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BIIB
DateTimeSourceHeadlineSymbolCompany
16/05/202412:30GlobeNewswire Inc.Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:BIIBBiogen Inc
16/05/202412:30PR Newswire (US)Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral SclerosisNASDAQ:BIIBBiogen Inc
15/05/202400:33GlobeNewswire Inc.Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer’s Disease Under the Fast Track StatusNASDAQ:BIIBBiogen Inc
15/05/202400:30PR Newswire (US)Eisai Initiates Rolling Biologics License Application to US FDA for LEQEMBI® (lecanemab-irmb) for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease Under the Fast Track StatusNASDAQ:BIIBBiogen Inc
02/05/202412:30GlobeNewswire Inc.Biogen Reports Progress on Corporate Responsibility PrioritiesNASDAQ:BIIBBiogen Inc
01/04/202400:30PR Newswire (US)Eisai Completes Submission of LEQEMBI® (lecanemab-irmb) Supplemental Biologics License Application for IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease to the U.S. FDANASDAQ:BIIBBiogen Inc
06/03/202412:30GlobeNewswire Inc.New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZA® (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene TherapyNASDAQ:BIIBBiogen Inc
04/03/202421:15GlobeNewswire Inc.Biogen Highlights New Data at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™) 2024 Annual MeetingNASDAQ:BIIBBiogen Inc
27/02/202400:54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
23/02/202412:00GlobeNewswire Inc.Biogen’s QALSODY® (tofersen), the First Therapy to Treat Rare, Genetic Form of ALS, Received Positive Opinion from CHMPNASDAQ:BIIBBiogen Inc
22/02/202415:12Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
22/02/202402:39Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202402:36Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202402:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202402:31Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202402:29Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202402:28Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
22/02/202402:27Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
21/02/202415:24Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BIIBBiogen Inc
21/02/202402:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202423:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202423:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202423:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202423:03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202423:01Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202422:56Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BIIBBiogen Inc
13/02/202412:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BIIBBiogen Inc
13/02/202400:11Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIIBBiogen Inc
13/02/202400:07Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:BIIBBiogen Inc
 Showing the most relevant articles for your search:NASDAQ:BIIB

Your Recent History

TSX
PKI
Parkland
NASDAQ
DPRO
Draganfly
LSE
0ITV
Gartner
NASDAQ
QADB
QAD
TSXV
RX
Biosyent
LSE
VTB
NASDAQ
ATSN
Artesyn
LSE
BOS
LSE
0RK9
Alligator Bioscience Ab
TSX
SVM
Silvercorp Metals
USOTC
JRSSD
JRSIS Health Care (PK)
NYSE
PEB
Pebblebrook Hotel
TG
CUP
Chugai Pharmaceutical
NASDAQ
REG
Regency Centers
USOTC
CMGR
Clubhouse Media (PK)
LSE
MDO
Mandarin Oriental Intern...
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved